Wait times and breast cancer survival: a population-based retrospective cohort study using CanIMPACT data.

Adjuvant chemotherapy Breast neoplasms Referral and consultation Survival analysis Time-to-treatment

Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 28 09 2023
accepted: 04 04 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

The time from breast cancer surgery to chemotherapy has been shown to affect survival outcomes; however, the effect of time from first breast cancer-related healthcare contact to first cancer specialist consultation, or the time from first breast cancer-related healthcare contact to adjuvant chemotherapy on survival has not been well explored. We aimed to determine whether various wait times along the breast cancer treatment pathway (contact-to-consultation, contact-to-chemotherapy, surgery-to-chemotherapy) were associated with overall survival in women within the Canadian province of Ontario. We performed a population-based retrospective cohort study of women diagnosed with stage I-III breast cancer in Ontario between 2007 and 2011 who received surgery and adjuvant chemotherapy. This was the Ontario cohort of a larger, nationwide study (the Canadian Team to improve Community-Based Cancer Care along the Continuum - CanIMPACT). We used Cox-proportional hazards regression to determine the association between the contact-to-consultation, contact-to-chemotherapy, and surgery-to-chemotherapy intervals and overall survival while adjusting for cancer stage, age, comorbidity, neighborhood income, immigration status, surgery type, and method of cancer detection. Among 12,782 breast cancer patients, longer surgery-to-chemotherapy intervals (HR 1.13, 95% CI 1.03-1.18 per 30-day increase), but not the contact-to-consultation (HR 0.979, 95% CI 0.95-1.01 per 30-day increase), nor the more comprehensive contact-to-chemotherapy intervals (HR 1.00, 95% CI 0.98-1.02 per 30-day increase) were associated with decreased survival in our adjusted analyses. Our findings emphasize the prognostic importance of a shorter surgery-to-chemotherapy interval, whereas the contact-to-consultation and contact-to-chemotherapy intervals have less impact on survival outcomes.

Identifiants

pubmed: 38748276
doi: 10.1007/s10552-024-01879-z
pii: 10.1007/s10552-024-01879-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660 pubmed: 33538338
Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2021. Canadian Cancer Society, pp 1–95
Powis M, Groome P, Biswanger N, Kendell C, Decker KM, Grunfeld E, McBride ML, Urquhart R, Winget M, Porter GA, Krzyzanowska MK (2019) Cross-Canada differences in early-stage breast cancer treatment and acute-care use. Curr Oncol 26(5):e624–e639
doi: 10.3747/co.26.5003 pubmed: 31708656 pmcid: 6821122
Bleicher RJ (2018) Timing and delays in breast cancer evaluation and treatment. Ann Surg Oncol 25(10):2829–2838
doi: 10.1245/s10434-018-6615-2 pubmed: 29968031 pmcid: 6123282
Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, Hamilton W, Hendry A, Hendry M, Lewis R, Macleod U, Mitchell ED, Pickett M, Rai T, Shaw K, Stuart N, Tørring ML, Wilkinson C, Williams B, Williams N, Emery J (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(Suppl 1):S92–S107
doi: 10.1038/bjc.2015.48 pubmed: 25734382 pmcid: 4385982
Ermiah E, Abdalla F, Buhmeida A, Larbesh E, Pyrhönen S, Collan Y (2012) Diagnosis delay in Libyan female breast cancer. BMC Res Notes 5(1):452
doi: 10.1186/1756-0500-5-452 pubmed: 22909280 pmcid: 3542159
Huo Q, Cai C, Zhang Y, Kong X, Jiang L, Ma T, Zhang N, Yang Q (2015) Delay in diagnosis and treatment of symptomatic breast cancer in China. Ann Surg Oncol 22(3):883–888
doi: 10.1245/s10434-014-4076-9 pubmed: 25212834
Tørring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P (2013) Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer (1990) 49(9):2187–2198
Tørring ML, Falborg AZ, Jensen H, Neal RD, Weller D, Reguilon I, Menon U, Vedsted P, Almberg SS, Anandan C, Barisic A, Boylan J, Cairnduff V, Donnelly C, Fourkala EO, Gavin A, Grunfeld E, Hammersley V, Hawryluk B, Kearney T, Kelly J, Knudsen AK, Lambe M, Law R, Lin Y, Malmberg M, Moore K, Turner D, White V (2019) Advanced-stage cancer and time to diagnosis: an International Cancer Benchmarking Partnership (ICBP) cross-sectional study. European Journal of Cancer Care 28(5):e13100
doi: 10.1111/ecc.13100 pubmed: 31119836
Lukács G, Kovács Á, Csanádi M, Moizs M, Repa I, Kaló Z, Vokó Z, Pitter JG (2019) Benefits of timely care in pancreatic cancer: a systematic review to navigate through the contradictory evidence. Cancer Manage Res 11:9849–9861
doi: 10.2147/CMAR.S221427
Redaniel MT, Martin RM, Ridd MJ, Wade J, Jeffreys M (2015) Diagnostic intervals and its association with breast, prostate, lung and colorectal cancer survival in England: historical cohort study using the Clinical Practice Research Datalink. PLoS One 10(5):e0126608
doi: 10.1371/journal.pone.0126608 pubmed: 25933397 pmcid: 4416709
Comber H, Cronin DP, Deady S, Lorcain PO, Riordan P (2005) Delays in treatment in the cancer services: impact on cancer stage and survival. Ir Med J 98(8):238–239
pubmed: 16255115
Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ (2019) Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS One 14(3):e0213209
doi: 10.1371/journal.pone.0213209 pubmed: 30822350 pmcid: 6396925
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O’Sullivan DE, Booth CM, Sullivan R, Aggarwal A (2020) Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 371(11):m4087
doi: 10.1136/bmj.m4087 pubmed: 33148535
Su Y, Zheng X, Ouyang Z (2021) The relationship between time to surgery (TTS) and survival in breast cancer: a systematic review and meta-analysis. Iran J Public Health 50(9):1773–1782
pubmed: 34722372 pmcid: 8542807
Cone EB, Marchese M, Paciotti M, Nguyen D, Nabi J, Cole AP, Molina G, Molina RL, Minami CA, Mucci LA, Kibel AS, Trinh Q (2020) Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers. JAMA Netw Open 3(12):e2030072
doi: 10.1001/jamanetworkopen.2020.30072 pubmed: 33315115 pmcid: 7737088
Raphael MJ, Biagi JJ, Kong W, Mates M, Booth CM, Mackillop WJ (2016) The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 160(1):17–28
doi: 10.1007/s10549-016-3960-3 pubmed: 27632288
Zhan Q, Fu J, Fu F, Zhang J, Wang C (2018) Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget 9(2):2739–2751
doi: 10.18632/oncotarget.23086 pubmed: 29416807
Kupstas AR, Hoskin TL, Day CN, Habermann EB, Boughey JC (2019) Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a national cancer database analysis. Ann Surg Oncol 26(10):3240–3249
doi: 10.1245/s10434-019-07566-7 pubmed: 31332635
Richards M, Westcombe A, Love S, Littlejohns P, Ramirez A (1999) Influence of delay on survival in patients with breast cancer: a systematic review. Lancet (British edition) 353(9159):1119–1126
Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, van Rijswijk E, Hiom S, Muth C, Beyer M, Neal RD (2012) The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer 106(7):1262–1267
doi: 10.1038/bjc.2012.68 pubmed: 22415239 pmcid: 3314787
Grunfeld E (2016) It takes a team: CanIMPACT: Canadian team to improve community-based cancer care along the continuum. Can Fam Physician 62(10):781–782
pubmed: 27737968 pmcid: 5063759
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329
doi: 10.1001/jamaoncol.2015.3856 pubmed: 26659132 pmcid: 5920529
Walsh RL, Lofters A, Moineddin R, Krzyzanowska M, Grunfeld E (2021) Primary care continuity and wait times to receiving breast cancer chemotherapy: a population-based retrospective cohort study using CanIMPACT data. Curr Oncol 28(6):4786–4804
doi: 10.3390/curroncol28060405 pubmed: 34898582 pmcid: 8628668
Brandt J, Garne JP, Tengrup I, Manjer J (2015) Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol 13:33
doi: 10.1186/s12957-014-0429-x pubmed: 25889186 pmcid: 4344734
Taheri M, Tavakol M, Akbari ME, Almasi-Hashiani A, Abbasi M (2019) Relationship of socio economic status, income, and education with the survival rate of breast cancer: a meta-analysis. Iran J Public Health 48(8):1428–1438
pubmed: 32292725 pmcid: 7145923
He X, Ye F, Zhao B, Tang H, Wang J, Xiao X, Xie X (2017) Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: a systematic review and meta-analysis involving 186982 patients. PLoS One 12(3):e0173862
doi: 10.1371/journal.pone.0173862 pubmed: 28301555 pmcid: 5354309
Cabral ALLV, Giatti L, Casale C, Cherchiglia ML (2019) Social vulnerability and breast cancer: differentials in the interval between diagnosis and treatment of women with different sociodemographic profiles. Cien Saude Colet 24(2):613–622
doi: 10.1590/1413-81232018242.31672016 pubmed: 30726393
Cheung MC, Earle CC, Fischer HD, Camacho X, Liu N, Saskin R, Shah BR, Austin PC, Singh S (2017) Impact of immigration status on cancer outcomes in Ontario, Canada. J Oncol Pract 13(7):e602–e612
doi: 10.1200/JOP.2016.019497 pubmed: 28605254
Johns Hopkins Medicine. ACG System Overview. Johns Hopkins ACG® System 2023, May 30
Moodley J, Cairncross L, Naiker T, Constant D (2018) From symptom discovery to treatment – women’s pathways to breast cancer care: a cross-sectional study. BMC Cancer 18(1):312
doi: 10.1186/s12885-018-4219-7 pubmed: 29562894 pmcid: 5863383
Austin PC, van Walraven C, Wodchis WP, Newman A, Anderson GM (2011) Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care 49(10):932–939
doi: 10.1097/MLR.0b013e318215d5e2 pubmed: 21478773 pmcid: 4617830
Maiz C, Silva F, Domínguez F, Galindo H, Camus M, León A, Oddó D, Villarroel A, Razmilic D, Navarro ME, Medina L, Merino T, Vines E, Peña J, Maldonado D, Pinto MP, Acevedo F, Sánchez C (2020) Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution. Ecancermedicalscience 14:1005
doi: 10.3332/ecancer.2020.1005 pubmed: 32104207 pmcid: 7039691
Saint-Jacques N, Younis T, Dewar R, Rayson D (2007) Wait times for breast cancer care. Br J Cancer 96(1):162–168
doi: 10.1038/sj.bjc.6603523 pubmed: 17179986
de Boniface J, Szulkin R, Johansson ALV (2021) Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: A Swedish national 6-year follow-up of 48 986 women. JAMA Surg 156(7):628–637
doi: 10.1001/jamasurg.2021.1438 pubmed: 33950173 pmcid: 8100916
SAS Institute Inc 2013. SAS, 9.4, Cary, NC, USA
Rosen RD, Sapra A. TNM Classification. 2023 Feb 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Vedsted P, Weller D, Zalounina Falborg A, Jensen H, Kalsi J, Brewster D, Lin Y, Gavin A, Barisic A, Grunfeld E, Lambe M, Malmberg M, Turner D, Harland E, Hawryluk B, Law R, Neal RD, White V, Bergin R, Harrison S, Menon U (2022) Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data. BMJ Open 12(12):e059669
doi: 10.1136/bmjopen-2021-059669 pubmed: 36521881 pmcid: 9756230
Statistics Canada, Table 17-10-0015-01 Estimates of the components of interprovincial migration, by age and gender, annual Mar 5
Statistics Canada, Table 17-10-0005-01 Population estimates on July 1, by age and gender, Mar 5
Huttunen T, Leidenius M, Jahkola T, Mattson J, Suominen S, Meretoja T (2022) Delay in the initiation of adjuvant chemotherapy in patients with breast cancer with mastectomy with or without immediate breast reconstruction. BJS Open 6(4):zrac096
doi: 10.1093/bjsopen/zrac096 pubmed: 35950555 pmcid: 9366640

Auteurs

Rachel Walsh (R)

Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. rachel.walsh@sunnybrook.ca.
Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. rachel.walsh@sunnybrook.ca.

Aisha Lofters (A)

Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Department of Family and Community Medicine, Women's College Hospital, Toronto, ON, Canada.

Patti Groome (P)

Queen's University, Kingston, ON, Canada.

Rahim Moineddin (R)

Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.

Monika Krzyzanowska (M)

Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Rebecca Griffiths (R)

ICES Queen's, Kingston, ON, Canada.

Eva Grunfeld (E)

Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.

Classifications MeSH